This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ReNeuron Group Bilan de santé

Santé financière contrôle des critères 4/6

ReNeuron Group possède un total de capitaux propres de £2.4M et une dette totale de £0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont £6.4M et de £4.0M.

Informations clés

Ratio d'endettement

UK£0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	UK£5.08m
Fonds propres	UK£2.42m
Total du passif	UK£4.00m
Total des actifs	UK£6.42m

Mises à jour récentes de la santé financière

Recent updates

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

Jul 15

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Jan 22

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Oct 12

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

Jun 04

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

Jan 12

Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)

Nov 20

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de RENE ( £5.7M ) dépassent ses passifs à court terme ( £3.8M ).

Passif à long terme: Les actifs à court terme de RENE ( £5.7M ) dépassent ses passifs à long terme ( £189.0K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: RENE est sans dette.

Réduire la dette: RENE n'a eu aucune dette au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: RENE dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: RENE dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de croître à un taux historique de 16 % chaque année.

This company listing is no longer active

ReNeuron Group Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

Recent updates

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024

ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

New minor risk - Profitability

ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023

ReNeuron Group plc, Annual General Meeting, Aug 22, 2023

Consensus EPS estimates upgraded to UK£0.10 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023

High number of new and inexperienced directors

ReNeuron Group plc Appoints Iain Ross as Executive Chairman

Consensus forecasts updated

First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)

No longer forecast to breakeven

Less than half of directors are independent

Less than half of directors are independent

ReNeuron Group plc Appoints John Hawkins as Chief Financial Officer

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

Price target decreased to UK£2.22

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022

Price target decreased to UK£2.19

ReNeuron Group plc, Annual General Meeting, Jul 14, 2022

Price target decreased to UK£2.04

ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022

ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive Director

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Price target decreased to UK£2.04

First half 2022 earnings: EPS and revenues miss analyst expectations

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

ReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial Officer

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

New 90-day high: UK£1.11

New 90-day low: UK£0.72

First half 2021 earnings released: UK£0.22 loss per share

New 90-day low: UK£0.78

Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)

ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020

New 90-day low: UK£0.85

Analysts update estimates

ReNeuron Group plc Auditor Raises 'Going Concern' Doubt

Full year earnings released - UK£0.36 loss per share

New 90-day low - UK£1.08

New 90-day low - UK£1.22

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines